|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MARCH5 |
Gene summary for MARCH5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MARCH5 | Gene ID | 54708 |
| Gene name | membrane associated ring-CH-type finger 5 | |
| Gene Alias | MARCH-V | |
| Cytomap | 10q23.32-q23.33 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q9NX47 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54708 | MARCH5 | LZE4T | Human | Esophagus | ESCC | 2.32e-13 | 5.02e-01 | 0.0811 |
| 54708 | MARCH5 | LZE5T | Human | Esophagus | ESCC | 3.25e-03 | 1.00e-01 | 0.0514 |
| 54708 | MARCH5 | LZE8T | Human | Esophagus | ESCC | 4.05e-13 | 4.41e-02 | 0.067 |
| 54708 | MARCH5 | LZE20T | Human | Esophagus | ESCC | 5.21e-04 | 1.46e-01 | 0.0662 |
| 54708 | MARCH5 | LZE22T | Human | Esophagus | ESCC | 8.94e-05 | 4.74e-01 | 0.068 |
| 54708 | MARCH5 | LZE24T | Human | Esophagus | ESCC | 1.14e-35 | 1.23e+00 | 0.0596 |
| 54708 | MARCH5 | P1T-E | Human | Esophagus | ESCC | 7.78e-09 | 7.26e-01 | 0.0875 |
| 54708 | MARCH5 | P2T-E | Human | Esophagus | ESCC | 2.22e-43 | 9.28e-01 | 0.1177 |
| 54708 | MARCH5 | P4T-E | Human | Esophagus | ESCC | 6.76e-37 | 9.69e-01 | 0.1323 |
| 54708 | MARCH5 | P5T-E | Human | Esophagus | ESCC | 1.72e-20 | 4.49e-01 | 0.1327 |
| 54708 | MARCH5 | P8T-E | Human | Esophagus | ESCC | 2.06e-26 | 4.78e-01 | 0.0889 |
| 54708 | MARCH5 | P9T-E | Human | Esophagus | ESCC | 2.12e-09 | 3.35e-01 | 0.1131 |
| 54708 | MARCH5 | P10T-E | Human | Esophagus | ESCC | 2.86e-18 | 2.88e-01 | 0.116 |
| 54708 | MARCH5 | P11T-E | Human | Esophagus | ESCC | 1.44e-15 | 8.61e-01 | 0.1426 |
| 54708 | MARCH5 | P12T-E | Human | Esophagus | ESCC | 1.25e-45 | 1.04e+00 | 0.1122 |
| 54708 | MARCH5 | P15T-E | Human | Esophagus | ESCC | 2.42e-33 | 7.69e-01 | 0.1149 |
| 54708 | MARCH5 | P16T-E | Human | Esophagus | ESCC | 7.67e-31 | 5.26e-01 | 0.1153 |
| 54708 | MARCH5 | P17T-E | Human | Esophagus | ESCC | 1.28e-10 | 2.98e-01 | 0.1278 |
| 54708 | MARCH5 | P19T-E | Human | Esophagus | ESCC | 1.13e-07 | 6.78e-01 | 0.1662 |
| 54708 | MARCH5 | P20T-E | Human | Esophagus | ESCC | 4.40e-26 | 6.98e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Liver | Cyst |  |
| Lung | IAC |  |
| Lung | AIS |  |
| Lung | AAH |  |
| Lung | MIAC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MARCH5 | SNV | Missense_Mutation | c.508N>T | p.Arg170Cys | p.R170C | Q9NX47 | protein_coding | deleterious(0.02) | probably_damaging(0.915) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| MARCH5 | SNV | Missense_Mutation | c.185N>C | p.Arg62Thr | p.R62T | Q9NX47 | protein_coding | tolerated(0.38) | benign(0.017) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| MARCH5 | SNV | Missense_Mutation | c.508N>T | p.Arg170Cys | p.R170C | Q9NX47 | protein_coding | deleterious(0.02) | probably_damaging(0.915) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
| MARCH5 | SNV | Missense_Mutation | novel | c.475N>C | p.Ile159Leu | p.I159L | Q9NX47 | protein_coding | tolerated(0.11) | benign(0.071) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| MARCH5 | SNV | Missense_Mutation | c.508N>T | p.Arg170Cys | p.R170C | Q9NX47 | protein_coding | deleterious(0.02) | probably_damaging(0.915) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MARCH5 | SNV | Missense_Mutation | novel | c.209N>G | p.Ala70Gly | p.A70G | Q9NX47 | protein_coding | deleterious(0) | benign(0.09) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MARCH5 | SNV | Missense_Mutation | novel | c.437T>G | p.Leu146Arg | p.L146R | Q9NX47 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| MARCH5 | SNV | Missense_Mutation | rs562101677 | c.731C>T | p.Ala244Val | p.A244V | Q9NX47 | protein_coding | tolerated(0.13) | benign(0.115) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| MARCH5 | SNV | Missense_Mutation | novel | c.239N>A | p.Gly80Asp | p.G80D | Q9NX47 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MARCH5 | SNV | Missense_Mutation | novel | c.560N>A | p.Gly187Asp | p.G187D | Q9NX47 | protein_coding | tolerated(0.47) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |